Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Angiomax bivalirudin: Post-marketing study data

In the international HORIZONS AMI trial in 3,600 patients presenting with a heart attack, Angiomax met the

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE